Enhertu is used in adults to treat the following kinds of cancer in certain situations. People receiving the drug must have received treatment for cancer in the past. Keep reading to learn about ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer. On Jan. 27, the Food and Drug Administration (FDA) ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

The new designation for Enhertu (trastuzumab deruxtecan) is based on the results of the DESTINY-Breast03 trial, which showed that the drug outperformed Roche's rival therapy Kadcyla (trastuzumab ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC ... nod for their original ADC, Enhertu. The U.S. regulator has cleared Enhertu ...

Enhertu belongs to a class of medicines called antibody-drug conjugates and is designed to target cancer cells while sparing the healthy ones. It combines a monoclonal antibody, trastuzumab ...

The approval emphasizes the importance of HER2 status testing in metastatic breast cancer to identify eligible patients for Enhertu treatment. The antibody drug conjugate was approved for patients ...

Enhertu, a specifically engineered HER2-directed antibody-drug conjugate (ADC), is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.